Pathophysiology News and Research

RSS

Complex associations underlie functional variance in schizophrenia

The complex associations between predictors and mediators of real-life functioning highlight the need for integrated and personalised treatment for patients with schizophrenia, say researchers in World Psychiatry.

8 Oct 2014

New study reports how TMS treatment works in people with depression

On Star Trek, it is easy to take for granted the incredible ability of futuristic doctors to wave small devices over the heads of both humans and aliens, diagnose their problems through evaluating changes in brain activity or chemistry, and then treat behavior problems by selectively stimulating relevant brain circuits.

30 Sep 2014

Weight cycling linked to relapse-prone bipolar course

Patients with bipolar disorder are more likely than healthy controls to have a history of weight cycling, which in turn is associated with an increased likelihood of manic and depressive episodes, researchers report.

25 Sep 2014

‘Missing’ schizophrenia heritability found

Researchers have matched up single nucleotide polymorphism sets with clinical syndromes to show that previously identified genetic variants can account for nearly all cases of schizophrenia.

25 Sep 2014

GWU researcher receives AHA grant to study diffuse brain swelling, injury in ICH patients

Shahram Majidi, M.D., a second-year resident in the Department of Neurology at the George Washington University School of Medicine and Health Sciences, received at $154K grant from the American Heart Association to study the presence of diffuse brain swelling and injury in patients with intracerebral hemorrhage (ICH).

22 Sep 2014

Resting-state brainwaves altered in schizophrenia

Patients with schizophrenia have increased resting-state gamma-band connectivity in a distinct region of the brain, and the increases correlate with clinical symptoms, research shows.

18 Sep 2014

New study sheds light on relationship between schizophrenia and smoking stems

Schizophrenia is associated with increased rates and intensity of tobacco smoking. A growing body of research suggests that the relationship between schizophrenia and smoking stems, in part, from an effort by patients to use nicotine to self-medicate symptoms and cognitive impairment associated with the disease.

17 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

21 Aug 2014

New articles shed light on PTSD, other mental health problems

Published today in the open access European Journal of Psychotraumatology is a collection of articles that offer rare and unique insight into the often fiercely debated topic of deployment related PTSD and associated mental health problems.

16 Aug 2014

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity.

13 Aug 2014

Schizophrenia-linked genetic variations and the developing brain: an interview with Prof. Guo-li Ming

How much is currently known about what happens in the developing brain that puts people at risk of schizophrenia?

11 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Study reveals novel epilepsy pathway linked to neurodegenerative diseases

A recent scientific discovery showed that mutations in prickle genes cause epilepsy, which in humans is a brain disorder characterized by repeated seizures over time. However, the mechanism responsible for generating prickle-associated seizures was unknown.

23 Jul 2014

Researchers collaborate to tackle rare diseases

Support from a network of leading researchers across Europe specialised in a rare auto-immune disease with unmet medical needs could help test several novel treatments

22 Jul 2014

Researchers propose ‘microbiome cloud model’ to understand variation in individual's microbiome composition

The Human Microbiome Project (HMP) is a global initiative to identify and characterize the microorganisms present at multiple sites in the human body.

22 Jul 2014

New book addresses safe and effective exercises for overweight children

Safe and Effective Exercise for Overweight Youth by Melinda Sothern, PhD, Director of Behavioral & Community Health Sciences and Professor of Research at the LSU Health Sciences Center New Orleans School of Public Health, provides exercise recommendations and guidelines specifically designed for overweight youth.

17 Jul 2014

Study to understand impairments of working memory among patients with schizophrenia

The inability to ignore irrelevant stimuli underlies the impaired working memory and cognition often experienced by individuals diagnosed with schizophrenia, reports a new study in the current issue of Biological Psychiatry.

15 Jul 2014

VENITI’s IDE receives FDA approval for VENITI VICI Venous Stent System

VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.

14 Jul 2014